Graves Diseases (Hormonal Disorders) - Drugs in Development, 2021

November 2021 | 102 pages | ID: G74E11480E19EN
Global Markets Direct

Abstracts

Graves Diseases (Hormonal Disorders) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Drugs In Development, 2021, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape.

Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 4 and 1 respectively.

Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders).
• The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Graves Diseases - Overview
Graves Diseases - Therapeutics Development
Graves Diseases - Therapeutics Assessment
Graves Diseases - Companies Involved in Therapeutics Development
Graves Diseases - Drug Profiles
Graves Diseases - Dormant Projects
Graves Diseases - Discontinued Products
Graves Diseases - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Graves Diseases, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Graves Diseases - Pipeline by advanceCor GmbH, 2021
Graves Diseases - Pipeline by Apitope International NV, 2021
Graves Diseases - Pipeline by AV7 Ltd, 2021
Graves Diseases - Pipeline by Cytodyn Inc, 2021
Graves Diseases - Pipeline by GlaxoSmithKline Plc, 2021
Graves Diseases - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Graves Diseases - Pipeline by Omeros Corp, 2021
Graves Diseases - Pipeline by OSE Immunotherapeutics, 2021
Graves Diseases - Pipeline by Virtici LLC, 2021
Graves Diseases - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Graves Diseases, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021